Prospective evaluation of the reliability, validity, and minimally important difference of the functional assessment of cancer therapy-gastric (FACT-Ga) quality-of-life instrument-Reference-Cited by-同舟云学术

Prospective evaluation of the reliability, validity, and minimally important difference of the functional assessment of cancer therapy-gastric (FACT-Ga) quality-of-life instrument

Published:2010-10-19 Issue:6 Volume:117 Page:1302-1312
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Garland Sheila N.,Pelletier Guy,Lawe Andrew,Biagioni Bradly J.,Easaw Jay,Eliasziw Michael,Cella David,Bathe Oliver F.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference33 articles.

1. World Health Organization http://www-dep.iarc.fr

2. The National Cancer Data Base Report on poor survival of US gastric carcinoma patients treated with gastrectomy: 5th ed. American Joint Committee on Cancer staging, proximal disease, and the “different disease” hypothesis;Hundahl;Cancer.,2000

3. Chemotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction;MacDonald;N Engl J Med.,2001

4. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer;Cunningham;N Engl J Med.,2006

5. Quality of life in patients with oesophageal and gastric cancer: an overview;Conroy;Oncology.,2006

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Methods for assessing quality of life in cancer;Rehabilitology;2024-09-06

2. Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial;LANCET GASTROENTEROL;2024

3. Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial;The Lancet Gastroenterology & Hepatology;2024-08

4. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial;Journal of Clinical Oncology;2024-06-10

5. Palliative Surgery for Patients with Gastroesophageal Junction or Gastric Cancer: A Report on Clinical Observational Outcomes;Annals of Surgical Oncology;2024-05-14